argenx SE or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, argenx SE and TG Therapeutics, Inc. have shown contrasting approaches to these costs. From 2014 to 2023, argenx SE's SG&A expenses surged by over 16,600%, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, TG Therapeutics, Inc. experienced a more modest increase of around 400% during the same period, indicating a more conservative approach.

A Decade of Financial Strategy

While argenx SE's strategy may suggest a focus on rapid growth and market penetration, TG Therapeutics, Inc.'s steadier increase could imply a focus on sustainable development. Understanding these strategies provides valuable insights into how biotech companies balance growth with cost management. As the industry evolves, these financial strategies will continue to shape their competitive landscapes.